Vacuum Erection Device Plus Once-Daily Tadalafil Improve Clinical Outcomes after Extracorporeal Shock Wave Therapy in Men Affected by Erectile Dysfunction Associated with Peyronie's Disease

被引:0
作者
Dell'Atti, Lucio [1 ]
Slyusar, Viktoria [2 ]
Ronchi, Piero [1 ]
Cambise, Chiara [3 ]
机构
[1] Univ Hosp Marche, Dept Urol, I-60126 Ancona, Italy
[2] Univ Hosp Marche, Pain Therapy Ctr, Div Anesthesia & Intens Care, I-60126 Ancona, Italy
[3] IRCSS, Univ Hosp Gemelli, Dept Emergency, I-00168 Rome, Italy
来源
LIFE-BASEL | 2024年 / 14卷 / 09期
关键词
Peyronie's disease; extracorporeal shockwave; vacuum erection device; erectile dysfunction; phosphodiesterase type 5 inhibitors; DOUBLE-BLIND; MANAGEMENT;
D O I
10.3390/life14091162
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The purpose of this study is to examine the combination of the mechanical effects of penile therapy with vacuum erection devices (VEDs) plus PDE5i, which improve clinical outcomes after extracorporeal shockwave therapy (ESWT) in men affected by erectile dysfunction (ED) associated with Peyronie's disease (PD). Methods: A total of 153 medical records of patients affected by PD in stable stage with ED and treated with ESWT were divided into two groups. Group A (GA) included 72 men treated with ESWT, mechanical stretching with VEDs and PDE5 & igrave; (Tadalafil 5 mg), and Group B (GB) included 81 men who received only ESWT plus Tadalafil 5 mg with the same protocol of GA. The patients in both groups were assessed at baseline and follow-up for erectile function, painful erections, penile plaque size, and penile curvature. The results were evaluated at baseline and 3, 6, and 12 months after the treatments. Results: Three months after the treatment, GA patients had a reduction in penile curvature degree from a mean +/- SD of 33.91 +/- 8.34 degrees at baseline to a mean +/- SD of 19.46 +/- 7.15 degrees after 12 months, whereas pain in an erection or during intercourse was resolved completely in 88.9% of the patients. The mean +/- SD IIEF-15 score of patients affected by severe/moderate ED further improved significantly in the GA group (p < 0.001) after 3, 6, and 12 months of treatment. There were no permanent adverse sequelae after treatments. Conclusions: The regular use of a VED plus Tadalafil in patients who had undergone ESWT significantly provided more benefit in patients with PD in terms of penile deformity, pain, and erectile function.
引用
收藏
页数:9
相关论文
共 26 条
  • [1] The Use of Vacuum Devices as Adjuvant Therapy before and after Penile Curvature Surgery in Patients Affected by La Peyronie's Disease: Results from a Comparative Study
    Cai, Tommaso
    Capece, Marco
    Ceruti, Carlo
    Tiscione, Daniele
    Puglisi, Marco
    Verze, Paolo
    Gontero, Paolo
    Palmieri, Alessandro
    [J]. CLINICS AND PRACTICE, 2023, 13 (05) : 1244 - 1252
  • [2] Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction
    Campbell, Jeffrey
    Alzubaidi, Raidh
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (01) : 46 - 59
  • [3] Technological Advancements for Treating Erectile Dysfunction and Peyronie's Disease
    Campbell, Jeffrey D.
    Matti, Danny
    Abed, Haider
    Di Pierdominico, Andrew
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2022, 49 (01) : 175 - 184
  • [4] A Novel Risk Calculator to Predict Erectile Dysfunction in HIV-Positive Men
    Chirca, Narcis
    Streinu-Cercel, Anca
    Stefan, Marius
    Aurelian, Justin
    Persu, Cristian
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (04):
  • [5] The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction
    Corona, G.
    Cucinotta, D.
    Di Lorenzo, G.
    Ferlin, A.
    Giagulli, V. A.
    Gnessi, L.
    Isidori, A. M.
    Maiorino, M. I.
    Miserendino, P.
    Murrone, A.
    Pivonello, R.
    Rochira, V.
    Sangiorgi, G. M.
    Stagno, G.
    Foresta, C.
    Lenzi, A.
    Maggi, M.
    Jannini, E. A.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2023, 46 (06) : 1241 - 1274
  • [6] Low-intensity laser diode plus extracorporeal shock wave therapy: a new treatment strategy in the management of Peyronie's disease
    Dell'Atti, Lucio
    Ronchi, Piero
    [J]. WORLD JOURNAL OF UROLOGY, 2023, 41 (09) : 2563 - 2568
  • [7] Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronies disease
    Dell'Atti, Lucio
    [J]. UROLOGY ANNALS, 2015, 7 (03) : 345 - 349
  • [8] Peyronie's disease development and management in diabetic men
    Gianazza, Simone
    Belladelli, Federico
    Leni, Riccardo
    Masci, Federica
    Rossi, Piercarlo
    Gianesini, Giuseppe
    Maggio, Paolo
    Zaffuto, Emanuele
    Salonia, Andrea
    Carcano, Giulio
    Deho, Federico
    Capogrosso, Paolo
    [J]. ANDROLOGY, 2023, 11 (02) : 372 - 378
  • [9] Low-Intensity Extracorporeal Shock Wave TherapyuA Novel Effective Treatment for Erectile Dysfunction in Severe ED Patients Who Respond Poorly to PDE5 Inhibitor Therapy
    Gruenwald, Ilan
    Appel, Boaz
    Vardi, Yoram
    [J]. JOURNAL OF SEXUAL MEDICINE, 2012, 9 (01) : 259 - 264
  • [10] Extracorporeal Shock Wave Therapy in Peyronie's Disease: Results of a Placebo-Controlled, Prospective, Randomized, Single-Blind Study
    Hatzichristodoulou, Georgios
    Meisner, Christoph
    Gschwend, Juergen E.
    Stenzl, Arnulf
    Lahme, Sven
    [J]. JOURNAL OF SEXUAL MEDICINE, 2013, 10 (11) : 2815 - 2821